Genentech is a rare success in the biotechnology industry. Hundreds of billions of dollars of venture capital was invested without the expected effect of transformation. Founded in 1976, Genentech was to develop a new science of recombinant DNA into viable therapeutic products with mass market appeal, the fact that most scientists agree, at least a decade. Founders, Herbert Boyer and Robert Swanson had limited financial resources, so they turned to Tom Perkins, co-founder of Kleiner Perkins-, for venture capital financing. Genentech developed by an effective union between scientific thinking and venture capital. In 1980, Genentech's IPO valued at $ 300 million. In 2009, it was fully acquired by the Swiss medical company Roche, for $ 47 billion. Roche held a majority stake in the company since 1990. "Hide
by G. Felda Hardymon, Tom Nicholas Source: Harvard Business School 17 pages. Publication Date: October 27, 2012. Prod. #: 813102-PDF-ENG
Related Case Solutions & Analyses:
Introduction to Business Government and the International Economy (BGIE) Course Overview
Meetup
Organizational Alignment Performance and Change in Professional Service Firms
Warren E. Buffett 2008
Bobbie DAlessandro and the Redesign of the Cambridge Rindge and Latin School
Flagstar Cos. Inc.
Wells Fargo Online Financial Services (A)
Spotify: Face the music
Walmart Inc. Takes on Amazon.com
MMA 801 Introduction to Management
